InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Hasnain Faheem, Président et CEO. Director active across 3 companies, notably Mirati Therapeutics, Inc.. Aggregated, 15 disclosures have been published. Split: 4 buys · 2 sells. Total volume traded: €1.8m. Activity tracked since 14 January 2022. The latest transaction was disclosed on 2 January 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Hasnain Faheem
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations15 total
280,000 shares0Common StockSEC:0001352620-26-000002:0
10,000 shares@ US$3.1216.9% of flowCommon StockSEC:0001193125-25-314154:0
437,500 shares0Common StockSEC:0001352620-25-000004:0
22,682 shares@ US$6.32100.0% of flowCommon StockSEC:0000950170-25-043903:0
372,000 shares@ US$0.67289.5% of flowCommon StockSEC:0001728117-24-000076:0
Canonical exit: 19 Sept 2024 (T+90)
23,172 shares@ US$1.15541.0% of flowCommon StockSEC:0001728117-24-000037:0
8,717 sharesCommon StockSEC:0001140361-24-003533:0
9,702 shares@ US$58.7565.3% of flowCommon StockSEC:0001628280-24-000294:0
10,791 shares@ US$27.8034.7% of flowCommon StockSEC:0001209191-23-045653:0
Canonical exit: 9 Nov 2023 (T+90)
540,176 shares@ US$1.8236.1% of flowCommon StockSEC:0001728117-23-000099:0
168,683 shares@ US$1.03446.6% of flowCommon StockSEC:0001728117-23-000018:0
Canonical exit: 18 Jun 2023 (T+90)
6,333 shares0Common StockSEC:0001214659-23-001046:0
138,696 shares@ US$7.2140.5% of flowCommon StockSEC:0001728117-22-000059:0
Canonical exit: 13 Oct 2022 (T+90)
19,035 shares@ US$8.9150.19% mcap100.0% of flowCommon StockSEC:0001728117-22-000031:0
3,619 shares0Common StockSEC:0001214659-22-000854:0
15 of 15 declarations
About Hasnain Faheem
Faheem Hasnain is the President and CEO of Mirati Therapeutics, Inc. and Gossamer Bio, Inc. He leads the strategic and commercial operations of both companies, focusing on innovation in the biotechnology field. With extensive experience in the pharmaceutical sector, he is responsible for strategic direction and growth. His leadership is essential for developing innovative treatments and improving patients' lives.
